oral BACE1-selective inhibitor

preclinical, QTc observed in dogs

from literature starting point

Journal of Medicinal Chemistry

Janssen Pharmaceutica NV

The Janssen BACE1-selective inhibitor, JNJ-67569762, was a preclinical candidate for Alzheimer’s disease. Obtaining BACE1 over BACE2 selectivity was a major challenge in the field, and the molecule is 74x selective…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.